Emerging evidence indicates that PP2A inactivation, caused either by mutations or by endogenous inhibitors, has a major role in the maintenance of the transformed phenotype in cancer, but its distinct tumour-intrinsic role in shaping the immune microenvironment and response to ICB remains unknown. The gene discussed is PTPA; the disease is cancer.